Oncogenomics and CYP450 Implications in Personalized Cancer Therapy

Author:

Udayaraja G.K.1,Emerson I. Arnold1ORCID

Affiliation:

1. Bioinformatics Programming Lab, Department of Biotechnology, School of Bio Sciences and Technology, VIT, Vellore – 632014, Tamil Nadu, India

Abstract

Background: The Human Genome Project has unleashed the power of genomics in clinical practice as a choice of individualized therapy, particularly in cancer treatment. Pharmacogenomics is an interdisciplinary field of genomics that deals with drug response, based on individual genetic makeup. Objective: The main genetic events associated with carcinogenesis activate oncogenes or inactivate tumor-suppressor genes. Therefore, drugs should be specific to inactivate or regulate these mutant genes and their protein products for effective cancer treatment. In this review, we summarize how polymedication decisions in cancer treatments based on the evaluation of cytochrome P450 (CYP450) polymorphisms are applied for pharmacogenetic assessment of anticancer therapy outcomes. Results: However, multiple genetic events linked, inactivating a single mutant gene product, may be insufficient to inhibit tumor progress. Thus, genomics and pharmacogenetics directly influence a patient’s response and aid in guiding clinicians to select the safest and most effective combination of medications for a cancer patient from the initial prescription. Conclusion: This review outlines the roles of oncogenes, the importance of cytochrome P450 (CYP450) in cancer susceptibility, and its impact on drug metabolism, proposing combined approaches to achieve precision therapy.

Publisher

Bentham Science Publishers Ltd.

Subject

Genetics(clinical),Pharmacology,Genetics,Molecular Biology,Molecular Medicine

Reference82 articles.

1. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. Globocan 2012; pp. 1-6.

2. Liu M-Z.; McLeod H.L.; He F-Z.; Chen X-P.; Zhao H-H.; Shu Y.; Epigenetic perspectives on cancer chemotherapy response. Pharmacogenomics 2014,15(5),699-715

3. Degtyarenko K.N.; Structural domains of P450-containing monooxygenase systems. Protein Eng 1995,8(8),737-747

4. Buck ML; The cytochrome P450 enzyme system and its effect on drug metabolism. Pediatr Pharmacother 1997

5. Barret K.E.; Barman S.M.; Brooks H.L.; Yuan J.X.J.; Ganong’s review of medical physiology 2012

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3